Overcoming the PosESBLities of Enterobacteriaceae Resistance
|
|
- Martina Allison
- 5 years ago
- Views:
Transcription
1 Overcoming the PosESBLities of Enterobacteriaceae Resistance Review of current treatment options Jamie Reed, PharmD Pharmacy Grand Rounds August 28, 2018 Rochester, MN 2018 MFMER slide-1
2 Disclosure No financial relationship(s) pertinent to this session Off-label use of the following medications will be discussed during this presentation, including: Meropenem Ertapenem Cefepime Piperacillin/Tazobactam Tigecycline Nitrofurantoin Fosfomycin Levofloxacin Ciprofloxacin Ceftolozane/Tazobactam Ceftazidime/Avibactam 2018 MFMER slide-2
3 Objectives Describe the resistance mechanism of extended-spectrum β-lactamase (ESBL) producing enterobacteriaceae Discuss evidence based treatment options for ESBL infections Review the role of carbapenem sparing regimens for the treatment of ESBL infections 2018 MFMER slide-3
4 What is an Extended Spectrum β- Lactamase (ESBL)? Plasmid mediated enzyme produced by Enterobacteriaceae causing resistance, including: Klebsiella spp. Escherichia coli Proteus spp. Resistance developed towards: Penicillins 1 st, 2 nd and 3 rd generation cephalosporins Monobactams Ghafourian S et al. Curr Issues Mol Biol : MFMER slide-4
5 Mechanism of ESBL Resistance O NH O NH O NH O NH OH Ghafourian S et al. Curr Issues Mol Biol : MFMER slide-5
6 Types of Extended Spectrum β-lactamases TEM SHV TEM SHV CTX-M OXA Ghafourian S et al. Curr Issues Mol Biol. 2015; 17: Bradford P. Clin Microbiol Rev. 2001; 14(4): MFMER slide-6
7 Prevalence of ESBLs In 2013 the CDC reported approximately 26,000 ESBL infections 1,700 deaths due to ESBL ESBL infection threat level is SERIOUS ESBL-EC: 10.5 cases per 100,000 patient days ESBL-KP: 5.3 cases per 100,000 patient days Thaden et al. Infect Control Hosp Epidemiol. 2016; 37(1): Ben-Ami et al. CID. 2006;42: MFMER slide-7
8 Question 1 What is the mechanism of ESBL resistance to penicillins, cephalosporins, and monobactams? A. Methylation of the β-lactam ring B. Hydrolysis of the β-lactam ring C. Efflux transport out of the cell D. Modified penicillin binding proteins 2018 MFMER slide-8
9 Question 1 What is the mechanism of ESBL resistance to penicillins, cephalosporins, and monobactams? A. Methylation of the β-lactam ring B. Hydrolysis of the β-lactam ring C. Efflux transport out of the cell D. Modified penicillin binding proteins 2018 MFMER slide-9
10 Treatment Considerations for ESBL Infections Source Severity Microbiology Drug Properties Effective treatment of ESBL infection Minimize risk of further resistance Tamma et al. Clin Infect Dis. 2017; 64: MFMER slide-10
11 Treatment Options for ESBL Infections Carbapenems β-lactams/β-lactamase inhibitors (βl-βlis) Generally drug of choice, especially in severe disease/high inoculum infections Cefepime, cephamycins Fluoroquinolones Fosfomycin Nitrofurantoin Tigecycline Tamma et al. Clin Infect Dis. 2017; 64: MFMER slide-11
12 ESBL Microbiological Result Example 2018 MFMER slide-12
13 β-lactams/β-lactamase Inhibitors (βl-βlis) Piperacillin/Tazobactam, Ampicillin/Sulbactam, Amoxicillin/Clavulanate 2018 MFMER slide-13
14 βl-βlis Debate for Treatment Efficacy βlis prevent hydrolysis of β-lactam ring Tazobactam Sulbactam Clavulanate Concern for inoculum effect with older βl-βlis Evidence for piperacillin/tazobactam in urinary or biliary sourced infections, conflicting evidence for blood stream infections Thomson et al. Antimicrob Agents Chemother. 2001; 45(12): Tamma et al. Clin Infect Dis. 2017; 64: MFMER slide-14
15 Tamma et al. PTZ vs Carbapenems for empiric ESBL bacteremia Retrospective chart review January 2007 to April adult patients with ESBL-E bacteremia treated empirically with: Piperacillin/tazobactam (PTZ) (n=103) Carbapenem (n=110) Primary outcome: mortality within 14 days from first day of detectable bacteremia Tamma et al. Clin Infect Dis. 2015; 60: MFMER slide-15
16 Tamma et al Results of PTZ for ESBL Infections Adjusted death risk is 1.92 times higher with PTZ vs carbapenems Bacteremia Source Incidence Catheter-related 46% Urinary 21% Intra-abdominal 17% Pneumonia 9% Biliary 9% Tamma et al. Clin Infect Dis. 2015; 60: MFMER slide-16
17 Tamma et al Conclusion Increased mortality with PTZ vs carbapenem for treatment of ESBL blood stream infections Catheter related, urinary, pneumonia, intraabdominal, biliary infections Carbapenems recommended first line therapy in severe disease Tamma et al. Clin Infect Dis. 2015; 60: MFMER slide-17
18 Gutierrez-Gutierrez et al. βl-βlis vs Carbapenems for ESBL Bacteremia Retrospective international study January 2004-December 2013 Adult patients with monomicrobial ESBL-E bacteremia Cohorts: empiric (n=365) vs definitive therapy (n=601) Primary outcome: clinical response at day 14 and 30 day mortality Gutierrez-Gutieerrez et al. Antimicrob Agents Chemother. 2016; 60: MFMER slide-18
19 Gutierrez-Gutierrez et al. Mortality of βlβlis for ESBL Bacteremia Infections βl-βlis Empiric Incidence Definitive Incidence Piperacillin/Tazobactam 72% 65% Ampicillin/Sulbactam 27% 35% Amoxicillin/Clavulanate 1% 0% Bacteremia Source Incidence Urinary 45% Biliary 12% Other 43% Gutierrez-Gutieerrez et al. Antimicrob Agents Chemother. 2016; 60: MFMER slide-19
20 Gutierrez-Gutierrez et al. Conclusion Similar mortality rates for βl-βlis vs carbapenems in blood stream infections due to ESBL-E βl-βlis could be considered an alternative option for complicated ESBL infections related to: Urinary or biliary sources Gutierrez-Gutieerrez et al. Antimicrob Agents Chemother. 2016; 60: MFMER slide-20
21 Studies Comparing βl-βli vs Carbapenems Author Organism Bacteremia Source Therapy Outcomes (βl-βli vs Carbapenem) Tamma et al K pneumoniae (68%) E coli (31%) P mirabilis (1%) Catheter, urinary, intra-abdominal, biliary, pneumonia PTZ (n=103) Carbapenem (n=110) Mortality at 14 days: 17% vs 8% (p<0.05) Mortality at 30 days: 26% vs 11% (p<0.01) Gutierrez- Gutierrez et al E coli (73%) K pneumoniae (19%) Urinary or biliary βl-βli Empiric (n=170) Definitive (n=92) Mortality at 30 day (empiric): 18% vs 20% (p=0.6) Carbapenem Empiric(n=195) Definitive(n=509) Mortality at 30 days (definitive): 10 % vs 14% (p=0.28) Tamma et al. Clin Infect Dis. 2017; 64: Ofer-Friedman et al. Infect Control Hosp Epidemiol. 2015; 36: Tamma et al. Clin Infect Dis. 2015; 60: Gutierrez-Gutieerrez et al. Antimicrob Agents Chemother. 2016; 60: MFMER slide-21
22 Summary of Piperacillin-Tazobactam for ESBL Treatment Recommended use in: Lower severity disease Urinary or biliary sources Lower inoculum infections Caution for use in severe disease due to inoculum effect Increased mortality shown in most studies with severe disease Tamma et al. Clin Infect Dis. 2017; 64: MFMER slide-22
23 Cefepime 2018 MFMER slide-23
24 Cefepime In vitro activity, inconsistent in vivo activity Increased mortality in treatment of ESBLs 2014 CLSI guidelines updated MICs: Susceptible MIC Susceptible-dose dependent MIC Resistant MIC 2 mcg/ml 4-8 mcg/ml 16 mcg/ml 2018 MFMER slide-24
25 Lee et al. Cefepime vs Carbapenems Retrospective, multicenter study May 2002-August patients included with monomicrobial ESBL-E bacteremia Cohorts: empiric (n=112) vs definitive therapy (n=178) Primary outcome: 30 day crude mortality Lee et al. Clin Infect Dis. 2013; 56: MFMER slide-25
26 Mortality Rates of Cefepime for ESBL Infections based on MIC Mortality (%) Sepsis-related 30-day Crude Cefepime MIC level (mcg/ml) Lee et al. Clin Infect Dis. 2013; 56: MFMER slide-26
27 Lee et al Results of Cefepime vs Carbapenems Bacteremia Source Incidence Pneumonia 24% Catheter-related 18% Urosepsis 18% Skin and soft tissue 15% Intra-abdominal 6% Cefepime Carbapenem Empiric Cohort Outcome Cefepime vs Carbapenems P value Sepsis-related mortality 47% vs 12% day mortality 59% vs 18% Crude mortality 65% vs 39% 0.07 Lee et al. Clin Infect Dis. 2013; 56: MFMER slide-27
28 Summary of Cefepime for ESBL Treatment Increased mortality compared to carbapenems Considered use in: Non-severe infections Low inoculum infections Susceptible MIC 2 mcg/ml Maximum dosing with MIC 4-8 Lee et al. Clin Infect Dis. 2013; 56: MFMER slide-28
29 Fluoroquinolones Ciprofloxacin, Levofloxacin, Moxifloxacin 2018 MFMER slide-29
30 Lo et al Fluoroquinolones vs Carbapenems in ESBL Bacteremia Retrospective, multicenter study in Taiwan and South Korea patients included with ESBL-E coli or ESBL-K pneumoniae bacteremia L0KZ9H Fluoroquinolone (n=24) vs Carbapenems (n=275) Primary outcome: 30 day mortality Lo et al. J Microb Immuno Infect. 2017; 50: MFMER slide-30
31 Lo et al. Fluoroquinolone Results FQ Bacteremia Source Incidence Urosepsis 29% Pneumonia 25% Catheter-related 21% Primary 13% Intra-abdominal 8% Skin and soft tissue 4% Fluoroquinolone Susceptibility Levofloxacin 34.7% Ciprofloxacin 28.9% Lo et al. J Microb Immuno Infect. 2017; 50: MFMER slide-31
32 Fluoroquinolone Summary Fluoroquinolones based on susceptibility, may be considered an alternative to carbapenems Mayo s antibiogram susceptibility E coli ~70% Klebsiella spp ~90% Additional resistance mechanisms can be developed towards fluoroquinolones Lo et al. J Microb Immuno Infect. 2017; 50: MFMER slide-32
33 Additional Treatment Options Nitrofurantoin Fosfomycin Tigecycline Ceftolozane-Tazobactam Ceftazidime-Avibactam Consider for lower urinary tract infections Increased mortality warnings Very expensive Not superior to carbapenems Restricted medications 2018 MFMER slide-33
34 Question 2 Which of the following antibiotics is associated with the greatest rate of survival for the treatment of an ESBL infection? A. Fosfomycin B. Cefepime C. Piperacillin-Tazobactam D. Meropenem 2018 MFMER slide-34
35 Question 2 Which of the following antibiotics is associated with the greatest rate of survival for the treatment of an ESBL infection? A. Fosfomycin B. Cefepime C. Piperacillin-Tazobactam D. Meropenem 2018 MFMER slide-35
36 Concern for Carbapenem Resistance Carbapenem Resistant Enterobacteriaceae (CRE) are an URGENT threat 9,000 infections per year 600 deaths per year Retrospective study at 22 centers in 4 countries: Average ICU LOS: 8 days Average LOS: 14 days 28-day mortality: 28.1% No clinical cure: 39.8% Alexander et al. Open Forum Infect Dis. 2017; MFMER slide-36
37 Carbapenem Sparing Regimens (CSR) CSR should be utilized in select cases to prevent the further development of CRE Treatment considerations should direct therapy: Urinary or Biliary Source Microbiology (MICs) Low Severity Drug Properties (PK/PD) Palacios-Baena et al. CID. 2017; 65: Tamma et al. CID. 2017; 65: Gutierrez-Gutierrez et al. Lancet Infect Dis. 2017; 17: MFMER slide-37
38 Question 3 A carbapenem sparing regimen could be recommended in the which of the following patients with a documented ESBL infection? A. Ventilator associated pneumonia B. Urinary tract infection C. Asymptomatic bacteriuria D. Bacterial Meningitis 2018 MFMER slide-38
39 Question 3 A carbapenem sparing regimen could be recommended in the which of the following patients with a documented ESBL infection? A. Ventilator associated pneumonia B. Urinary tract infection C. Asymptomatic bacteriuria D. Bacterial Meningitis 2018 MFMER slide-39
40 Summary ESBL resistance is caused by an enzyme that hydrolyzes the beta-lactam to inactivate the drug Carbapenems are first-line therapy for documented ESBL infections Alternative therapy considerations include source, severity, microbiology, and drug properties Carbapenem sparing regimens should be considered when possible to reduce risk of CRE 2018 MFMER slide-40
41 Questions & Discussion 2018 MFMER slide-41
42 Overcoming the PosESBLities of Enterobacteriaceae Resistance Review of current treatment options Jamie Reed, PharmD Pharmacy Grand Rounds August 28, 2018 Rochester, MN 2018 MFMER slide-42
Treatment Options for Urinary Tract Infections Caused by Extended-Spectrum Β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae
Treatment Options for Urinary Tract Infections Caused by Extended-Spectrum Β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae medicine.missouri.edu/jahm/treatment-options-urinary-tract-infections-caused-extended-spectrum-β-lactamase-producingescherichia-coli-klebsiella-pneumoniae/
More informationDisclosure. Objectives. Evolution of β Lactamases. Extended Spectrum β Lactamases: The New Normal. Prevalence of ESBL Mystic Program
47 th Annual Meeting August 2-4, 2013 Orlando, FL Extended Spectrum β Lactamases: The New Normal Disclosure I do have a vested interest in or affiliation with the following companies or organizations Triax
More informationAntibacterial Antibiotic Resistancein 2016 What Should an Internist Know? Disclosures. Objectives 3/6/2016. Achaogen: Allergan:
Antibacterial Antibiotic Resistancein 2016 What Should an Internist Know? Michael Satlin, MD, MS Assistant Professor of Medicine Division of Infectious Diseases Weill Cornell Medicine March 4, 2016 1 Disclosures
More informationReporting blood culture results to clinicians: MIC, resistance mechanisms, both?
Reporting blood culture results to clinicians: MIC, resistance mechanisms, both? Christian G. Giske, MD, PhD Senior Consultant Physician/Associate Professor Department of Clinical Microbiology Karolinska
More informationUrinary Tract Infections: From Simple to Complex. Adriane N Irwin, MS, PharmD, BCACP Clinical Assistant Professor Ambulatory Care October 25, 2014
Urinary Tract Infections: From Simple to Complex Adriane N Irwin, MS, PharmD, BCACP Clinical Assistant Professor Ambulatory Care October 25, 2014 Learning Objectives Develop empiric antimicrobial treatment
More informationFrequency of Occurrence and Antimicrobial Susceptibility of Bacteria from ICU Patients with Pneumonia
Frequency of Occurrence and Antimicrobial Susceptibility of Bacteria from ICU Patients with Pneumonia Helio S. Sader, M.D.* Mariana Castanheira, Ph.D. Rodrigo E. Mendes, Ph.D. Robert K. Flamm, Ph.D. JMI
More informationUpdate on CLSI and EUCAST
Update on CLSI and EUCAST 1 Completed work» Cephalosporin breakpoints for Enterobacteriaceae ESBL screens MIC versus resistance mechanism» Carbapenem breakpoints for Enterobacteriaceae Modified Hodge Test»
More informationGiving the Proper Dose: How Can The Clinical and Laboratory Standards Institute(CLSI)Help?
Giving the Proper Dose: How Can The Clinical and Laboratory Standards Institute(CLSI)Help? Pranita D. Tamma, M.D., M.H.S. Director, Pediatric Antimicrobial Stewardship Johns Hopkins University School of
More informationTreatment Strategies for Infections due to MDR-GNR
Treatment Strategies for Infections due to MDR-GNR Michael Satlin, MD Instructor in Medicine Division of Infectious Diseases Weill Cornell Medical College, New York, NY October 16, 2012 1 2 Faculty Disclosure
More informationHelen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory, Institute of Environmental Science and Research Limited (ESR); July 2014.
Annual survey of extended-spectrum -lactamase (ESBL)-producing Enterobacteriaceae, 2013 Helen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory, Institute of Environmental Science and Research
More information(DHA-1): Microbiologic and Clinical Implications
AAC Accepts, published online ahead of print on 20 September 2010 Antimicrob. Agents Chemother. doi:10.1128/aac.00083-10 Copyright 2010, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationAntibiotic Treatment of GNR MDR Infections. Stan Deresinski
Antibiotic Treatment of GNR MDR Infections Stan Deresinski Kucers: The Use of Antibiotics 1st Edition 1972 392 pages Kucers: The Use of Antibiotics 7 th Edition 2017 5338 pages Carbapenem Susceptibility
More informationNightmare Bacteria. Disclosures. Technician Objectives. Pharmacist Objectives. Carbapenem Resistance in Carbapenem Resistance in 2017
Nightmare Bacteria How to Deal with the Reality of Carbapenem-resistant Organisms Disclosures I have no conflicts of interest relative to the content of this presentation Matthew L. Brown, Pharm.D., BCPS
More informationMICHIGAN MEDICINE GUIDELINES FOR TREATMENT OF URINARY TRACT INFECTIONS IN ADULTS
When to Order a Urine Culture: Asymptomatic bacteriuria is often treated unnecessarily, and accounts for a substantial burden of unnecessary antimicrobial use. National guidelines recommend against testing
More informationPublic Health Surveillance for Multi Drug Resistant Organisms in Orange County
Public Health Surveillance for Multi Drug Resistant Organisms in Orange County Matt Zahn, MD Medical Director Epidemiology and Assessment Orange County Public Health Antimicrobial Mechanisms of Action
More informationDiscussion points CLSI M100 S19 Update. #1 format of tables has changed. #2 non susceptible category
Discussion points 2009 CLSI M100 S19 Update Nebraska Public Health Laboratory Changes most important to routine antimicrobial susceptibility testing. Documents available Janet Hindler discussion slide
More informationLaboratory CLSI M100-S18 update. Paul D. Fey, Ph.D. Associate Professor/Associate Director Josh Rowland, M.T. (ASCP) State Training Coordinator
Nebraska Public Health Laboratory 2008 CLSI M100-S18 update Paul D. Fey, Ph.D. Associate Professor/Associate Director Josh Rowland, M.T. (ASCP) State Training Coordinator Agenda Discuss 2008 M100- S18
More informationALERT. Clinical microbiology considerations related to the emergence of. New Delhi metallo beta lactamases (NDM 1) and Klebsiella
ALERT Clinical microbiology considerations related to the emergence of New Delhi metallo beta lactamases (NDM 1) and Klebsiella pneumoniae carbapenemases (KPC) amongst hospitalized patients in South Africa
More informationST11 KPC-2 Klebsiella pneumoniae detected in Taiwan
AAC Accepts, published online ahead of print on 30 January 2012 Antimicrob. Agents Chemother. doi:10.1128/aac.05576-11 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 3 4 5
More informationDetermining the Optimal Carbapenem MIC that Distinguishes Carbapenemase-Producing
AAC Accepted Manuscript Posted Online 8 August 2016 Antimicrob. Agents Chemother. doi:10.1128/aac.00838-16 Copyright 2016, American Society for Microbiology. All Rights Reserved. 1 1 2 Determining the
More informationβ- Lactamase Gene carrying Klebsiella pneumoniae and its Clinical Implication
Prevalence of Carbapenem-Hydrolyzing β- Lactamase Gene carrying Klebsiella pneumoniae and its Clinical Implication David Alcid M.D Balaji Yegneswaran M.D. Wanpen Numsuwan Introduction Klebsiella pneumoniae
More informationPharmacologyonline 1: (2010) ewsletter Singh and Kochbar. Optimizing Pharmacokinetic/Pharmacodynamics Principles & Role of
Optimizing Pharmacokinetic/Pharmacodynamics Principles & Role of Cefoperazone Sulbactam Singh M*, Kochhar P* Medical & Research Division, Pfizer India. Summary Antimicrobial resistance is associated with
More informationActivity of Ceftolozane/Tazobactam Against a Broad Spectrum of Recent Clinical Anaerobic Isolates
AAC Accepts, published online ahead of print on 25 November 2013 Antimicrob. Agents Chemother. doi:10.1128/aac.02253-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. Activity
More informationβ-lactamase inhibitors
β-lactamase inhibitors Properties, microbiology & enzymology DAVID M LIVERMORE Professor of Medical Microbiology, UEA Lead on Antibiotic Resistance, Public Health England β-lactamase classes A B C D Serine
More informationSurveillance of antimicrobial susceptibility of Enterobacteriaceae pathogens isolated from intensive care units and surgical units in Russia
Feb. 2016 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 1 41 41 Surveillance of antimicrobial susceptibility of Enterobacteriaceae pathogens isolated from intensive care units and surgical units in Russia IRINA
More informationClinical significance of extended-spectrum
Clinical significance of extended-spectrum β-lactamases Expert Rev. Anti Infect. Ther. 6(5), 671 683 (2008) Jesús Rodríguez-Baño and Alvaro Pascual Author for correspondence Sección de Enfermedades Infecciosas,
More informationPrevalence of Extended Spectrum -Lactamases In E.coli and Klebsiella spp. in a Tertiary Care Hospital
ISSN: 2319-7706 Volume 3 Number 10 (2014) pp. 474-478 http://www.ijcmas.com Original Research Article Prevalence of Extended Spectrum -Lactamases In E.coli and Klebsiella spp. in a Tertiary Care Hospital
More informationControversial Issues in Susceptibility Testing: Point/Counterpoint. April N. Abbott, PhD D(ABMM) Romney M. Humphries, PhD D(ABMM)
Controversial Issues in Susceptibility Testing: Point/Counterpoint April N. Abbott, PhD D(ABMM) Romney M. Humphries, PhD D(ABMM) Disclosures RMH: Funding from BD, biomerieux, Beckman-Coulter, GenMark,
More informationEmergence of Klebsiella pneumoniae ST258 with KPC-2 in Hong Kong. Title. Ho, PL; Tse, CWS; Lai, EL; Lo, WU; Chow, KH
Title Emergence of Klebsiella pneumoniae ST258 with KPC-2 in Hong Kong Author(s) Ho, PL; Tse, CWS; Lai, EL; Lo, WU; Chow, KH Citation International Journal Of Antimicrobial Agents, 2011, v. 37 n. 4, p.
More informationIn Vitro Activity of Ceftazidime-Avibactam Against Isolates. in a Phase 3 Open-label Clinical Trial for Complicated
AAC Accepted Manuscript Posted Online 21 November 2016 Antimicrob. Agents Chemother. doi:10.1128/aac.01820-16 Copyright 2016, American Society for Microbiology. All Rights Reserved. 1 2 3 4 5 6 7 8 9 10
More informationClinical Microbiology Newsletter
Clinical Microbiology Newsletter $88 Vol. 30, No. 10 www.cmnewsletter.com May 15, 2008 Newer β-lactamases: Clinical and Laboratory Implications, Part I * Ellen Smith Moland, B.S.M.T., Soo-Young Kim, M.D.,
More informationRevised AAC Version 2» New-Data Letter to the Editor ACCEPTED. Plasmid-Mediated Carbapenem-Hydrolyzing β-lactamase KPC-2 in
AAC Accepts, published online ahead of print on 3 December 2007 Antimicrob. Agents Chemother. doi:10.1128/aac.01180-07 Copyright 2007, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationExpert rules. for Gram-negatives
Academic Perspective in Expert rules Emerging Issues of Resistance in Gram-ve Bacteria for Gram-negatives Trevor Winstanley Sheffield Teaching Hospitals Presented on behalf of David Livermore University
More informationExpert rules in antimicrobial susceptibility testing: State of the art
Expert rules in antimicrobial susceptibility testing: State of the art ESCMID Postgraduate Education Course Antimicrobial Susceptibility Testing and Surveillance: from Laboratory to Clinic Hospital Universitario
More informationCefmetazole for bacteremia caused by ESBL-producing enterobacteriaceae comparing with carbapenems
Fukuchi et al. BMC Infectious Diseases (2016) 16:427 DOI 10.1186/s12879-016-1770-1 RESEARCH ARTICLE Open Access Cefmetazole for bacteremia caused by ESBL-producing enterobacteriaceae comparing with carbapenems
More informationJournal of Infectious Diseases and
Journal of Infectious Diseases & Therapy ISSN: 2332-0877 Journal of Infectious Diseases and Therapy Santanirand et al., J Infect Dis Ther 2018, 6:5 DOI: 10.4172/2332-0877.1000378 Research Article Open
More informationCarbapenem-resistant Escherichia coli and Klebsiella pneumoniae in Taiwan
Carbapenem-resistant Escherichia coli and Klebsiella pneumoniae in Taiwan An Infection Control Emergency Speaker: L Kristopher Siu Principal Investigator Division of Infectious Diseases National Institute
More informationAcademic Perspective in. David Livermore Prof of Medical Microbiology, UEA Lead on Antibiotic resistance PHE
Academic Perspective in Emerging No, we can t Issues treat of carbapenemase Resistance and ESBL in Gram-ve producers Bacteria based on MIC David Livermore Prof of Medical Microbiology, UEA Lead on Antibiotic
More informationCarbapenems and Enterobacteriaceae
Title Carbapenems and Enterobacteriaceae Presenter s details NHLS Dr Khine Swe Swe/Han FC Path ( Micro), SA MMed( micro), SA DTMH(Wits univ),sa PDIC(Stellen univ)sa MB,BS(Yangon),Myanmar Pathologist,Consultant/Lecturer,
More informationOriginal Article - Infection/Inflammation. Sungmin Song, Chulsung Kim, Donghoon Lim.
www.kjurology.org http://dx.doi.org/10.4111/kju.2014..4.20 Original Article - Infection/Inflammation http://crossmark.crossref.org/dialog/?doi=10.4111/kju.2014..4.20&domain=pdf&date_stamp=2014-04-1 Clinical
More informationPlazomicin for complicated urinary tract infection
October 2016 Horizon Scanning Research & Intelligence Centre Plazomicin for complicated urinary tract infection NIHR HSRIC ID: 9787 Lay summary Serious infections caused by Gram-negative bacteria are becoming
More informationClinical Management of Infections Caused by Enterobacteriaceae that Express Extended- Spectrum β-lactamase and AmpC Enzymes
56 Clinical Management of Infections Caused by Enterobacteriaceae that Express Extended- Spectrum β-lactamase and AmpC Enzymes Patrick N. A. Harris, BSc, MBBS, MRCP, DTM&H, FRACP, FRCPA 1 1 Infection and
More informationAnnual Surveillance Summary: Klebsiella species Infections in the Military Health System (MHS), 2017
i Annual Surveillance Summary: Klebsiella species Infections in the Military Health System (MHS), 2017 Tej Mishra and Uzo Chukwuma Approved for public release. Distribution is unlimited. The views expressed
More informationAAC Accepts, published online ahead of print on 13 October 2008 Antimicrob. Agents Chemother. doi: /aac
AAC Accepts, published online ahead of print on 13 October 2008 Antimicrob. Agents Chemother. doi:10.1128/aac.00931-08 Copyright 2008, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationTreatment Options for Carbapenem-Resistant Enterobacteriaceae Infections
REVIEW ARTICLE Treatment Options for Carbapenem-Resistant Enterobacteriaceae Infections Haley J. Morrill, 1,2 Jason M. Pogue, 3 Keith S. Kaye, 4 and Kerry L. LaPlante 1,2,5 1 Veterans Affairs Medical Center,
More informationPerspectives on emerging multidrug resistant organisms in the pediatric setting
Perspectives on emerging multidrug resistant organisms in the pediatric setting Ombeva Malande Vaccinologist/Paed infectious diseases Specialist Lecturer Makerere/Egerton University 27 th April 2018; 18th
More informationA Snapshot of Colistin Use in South-East Europe and Particularly in Greece
A Snapshot of Colistin Use in South-East Europe and Particularly in Greece Helen Giamarellou 02.05.2013 When Greek Physicians Prescribe Colistin? It is mainly prescribed in the ICU for VAP, bacteremia
More informationIn Vitro Susceptibility Pattern of Cephalosporin- Resistant Gram-Negative Bacteria
In Vitro Susceptibility Pattern of Cephalosporin- Resistant Gram-Negative Bacteria Warunee Punpanich MD*, Worraporn Tantichattanon MD**, Siriporn Wongwatcharapaiboon MD**, Vipa Treeratweeraphong BSc, MSc***
More informationNo Need to Agonize! Tips for the Diagnosis and Treatment of Complicated UTIs
ASCENSION TEXAS No Need to Agonize! Tips for the Diagnosis and Treatment of Complicated UTIs Austin Area Society of Health-System Pharmacists April 26, 2018 Amy Carr, PharmD PGY-2 Infectious Diseases Pharmacy
More informationUse of imipenem. with the support of Wallonie-Bruxelles International. Magali Dodémont Microbiology Hospital Erasme Université Libre de Bruxelles
with the support of Wallonie-Bruxelles International Use of imipenem Magali Dodémont Microbiology Hospital Erasme Université Libre de Bruxelles 1 Β-lactams classification 2 Β-lactams: mode of action Inhibition
More informationOther β-lactam. A. Carbapenems:
A. Carbapenems: Other β-lactam Carbapenems are synthetic β-lactam antibiotics Differ in structure from the penicillins in that the sulfur atom of the thiazolidine ring. Imipenem, meropenem, doripenem,
More informationClinical Practice Guidelines for the Antibiotic Treatment of Community-Acquired Urinary Tract Infections
Special Article https://doi.org/10.3947/ic.2018.50.1.67 Infect Chemother 2018;50(1):67-100 ISSN 2093-2340 (Print) ISSN 2092-6448 (Online) Infection & Chemotherapy Clinical Practice Guidelines for the Antibiotic
More informationESCMID Online Lecture Library. by author
www.eucast.org EXPERT RULES IN ANTIMICROBIAL SUSCEPTIBILITY TESTING Dr. Rafael Cantón Hospital Universitario Ramón y Cajal SERVICIO DE MICROBIOLOGÍA Y PARASITOLOGÍA Departamento de Microbiología II Universidad
More informationGuess or get it right?
Guess or get it right? Antimicrobial prescribing in the 21 st century Robert Masterton Traditional Treatment Paradigm Conservative start with workhorse antibiotics Reserve more potent drugs for non-responders
More informationNew insights in antibiotic and antifungal therapy in the compromised host
New insights in antibiotic and antifungal therapy in the compromised host Claudio Viscoli University of Genova Ospedale Policlinico San Martino, Genova Potential conflicts of interest (last 5 years) Received
More informationAcute Cholangitis. Kelsey Knotts PharmD Candidate Class of 2016
Acute Cholangitis Kelsey Knotts PharmD Candidate Class of 2016 Learning Objectives 1. Describe the mechanism of the development of acute cholangitis 2. Identify common causative organisms in acute cholangitis
More informationIn-House Standardization of Carba NP Test for Carbapenemase Detection in Gram Negative Bacteria
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 7 Number 01 (2018) Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2018.701.342
More informationDiane M. Gomes, Pharm.D. Outcomes in Antimicrobial Stewardship Post-Doctoral Pharmacy Fellow Providence Veterans Affairs Medical Center
Diane M. Gomes, Pharm.D. Outcomes in Antimicrobial Stewardship Post-Doctoral Pharmacy Fellow Providence Veterans Affairs Medical Center The information disseminated in this lecture is given in my personal
More informationjmb Research Article Review Semi Kim 1, Ji Youn Sung 2, Hye Hyun Cho 3, Kye Chul Kwon 1, and Sun Hoe Koo 1 *
J. Microbiol. Biotechnol. (2014), 24(6), 765 770 http://dx.doi.org/10.4014/jmb.1306.06036 Review Research Article jmb Characterization of CTX-M-14- and CTX-M-15-Producing Escherichia coli and Klebsiella
More informationNDA Briefing Document Anti-Infective Drugs Advisory Committee 05 December 2014
CEFTAZIDIME-AVIBACTAM FOR INJECTION for Treatment of Complicated Intra-abdominal Infection (used in combination with metronidazole), Complicated Urinary Tract Infection including Acute Pyelonephritis,
More informationAnnual Surveillance Summary: Pseudomonas aeruginosa Infections in the Military Health System (MHS), 2016
Annual Surveillance Summary: Pseudomonas aeruginosa Infections in the Military Health System (MHS), 2016 Sarah Gierhart and Uzo Chukwuma Approved for public release. Distribution is unlimited. The views
More informationNEW DEVELOPMENTS AND CHALLENGING CASES IN HOSPITAL INFECTIOUS DISEASES
Lisa G. Winston, MD Professor, University of California, San Francisco Vice Chief, Inpatient Medical Services and Hospital Epidemiologist, San Francisco General Hospital NEW DEVELOPMENTS AND CHALLENGING
More informationSepsis Treatment: Early Identification Remains the Key Issue
Sepsis Treatment: Early Identification Remains the Key Issue Marin H. Kollef, MD Professor of Medicine Washington University School of Medicine Director, Medical Critical Care Director, Respiratory Care
More informationAntibiotic Resistance Pattern of Blood and CSF Culture Isolates At NHLS Academic Laboratories (2005)
Antibiotic Resistance Pattern of Blood and CSF Culture Isolates At NHLS Academic Laboratories (2005) Streptococcus pneumoniae (SP) Blood Culture Isolates Penicillin intermediate Penicillin Cefotaxime 336
More informationNONFERMENTING GRAM NEGATIVE RODS. April Abbott Deaconess Health System Evansville, IN
NONFERMENTING GRAM NEGATIVE RODS April Abbott Deaconess Health System Evansville, IN OBJECTIVES Discuss basic limitations to assessing carbapenem resistance in nonfermenting GNRs Discuss antimicrobial
More informationMolecular characterisation of CTX-M-type extendedspectrum β-lactamases of Escherichia coli isolated from a Portuguese University Hospital
EJHP Science Volume 17 2011 Issue 3 P. 1-5 2011 Pharma Publishing and Media Europe. All rights reserved 1781-7595 25 www.ejhp.eu Molecular characterisation of CTX-M-type extendedspectrum β-lactamases of
More informationDifferentiation of Carbapenemase producing Enterobacteriaceae by Triple disc Test
Original article: Differentiation of Carbapenemase producing Enterobacteriaceae by Triple disc Test Manish Bansal 1, Nitya Vyas 2, Babita Sharma 3, R.K.Maheshwari 4 1PG Resident, 2 Professor, 3 Assistant
More informationAnalysis of Klebsiella pneumoniae bacteremia in Patients from Mexico hospital
ISSN 0001-6012/2016/58/2/62-67 Acta Médica Costarricense, 2016 Colegio de Médicos y Cirujanos de Costa Rica Original Analysis of Klebsiella pneumoniae bacteremia in Patients from Mexico hospital Christian
More informationEAU GUIDELINES ON UROLOGICAL INFECTIONS
EAU GUIDELINES ON UROLOGICAL INFECTIONS (Limited text update March 2018) G. Bonkat (Co-chair), R. Pickard (Co-chair), R. Bartoletti, T. Cai, F. Bruyere, S.E. Geerlings, B. Köves, F. Wagenlehner Guidelines
More informationAntibiotics to treat multi-drug-resistant bacterial infections
Antibiotics to treat multi-drug-resistant bacterial infections July 2013 JUNE 2013 Copyright 2013 Tetraphase Pharmaceuticals, Inc. 1 Forward Looking Statements and Other Important Cautions Any statements
More informationLa farmacologia in aiuto
Ferrara, 15 giugno 2018 La farmacologia in aiuto Pier Giorgio Cojutti, Federico Pea Istituto di Farmacologia Clinica Azienda Sanitaria Universitaria Integrata di Udine Therapeutic Drug Monitoring of Beta-Lactams
More informationAffinity of Doripenem and Comparators to Penicillin-Binding Proteins in Escherichia coli and ACCEPTED
AAC Accepts, published online ahead of print on February 00 Antimicrob. Agents Chemother. doi:./aac.01-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationIN VITRO ACTIVITY OF POLYMYXIN B AND MEROPENEM ALONE AND IN COMBINATION AGAINST CARBAPENEM- RESISTANT ENTEROBACTERIACEAE
University of Kentucky UKnowledge Theses and Dissertations--Pharmacy College of Pharmacy 2016 IN VITRO ACTIVITY OF POLYMYXIN B AND MEROPENEM ALONE AND IN COMBINATION AGAINST CARBAPENEM- RESISTANT ENTEROBACTERIACEAE
More informationCarbapenemases in Enterobacteriaceae: Prof P. Nordmann Bicêtre hospital, South-Paris Med School
Carbapenemases in Enterobacteriaceae: 2012 Prof P. Nordmann Bicêtre hospital, South-Paris Med School March 21, 2012 Trends in Molecular Medecine NDM IMP OXA-48 KPC VIM ALERT VI M KPC KPC NDM I MP OXA-
More informationYu Bin Seo 1, Jacob Lee 1, Young Keun Kim 2, Seung Soon Lee 3, Jeong-a Lee 3, Hyo Youl Kim 2, Young Uh 4, Han-Sung Kim 5 and Wonkeun Song 6*
Seo et al. BMC Infectious Diseases (2017) 17:404 DOI 10.1186/s12879-017-2502-x RESEARCH ARTICLE Open Access Randomized controlled trial of piperacillintazobactam, cefepime and ertapenem for the treatment
More informationScreening and detection of carbapenemases
Screening and detection of carbapenemases For many isolates with carbapenemases the MICs of carbapenems are around the susceptible breakpoint making resistance difficult to detect - particularly with automated
More informationbreakpoints, cephalosporins, CLSI, Enterobacteriacae, EUCAST, review Clin Microbiol Infect 2008; 14 (Suppl. 1):
REVIEW Breakpoints for intravenously used cephalosporins in Enterobacteriaceae EUCAST and CLSI breakpoints G. Kahlmeter Department of Clinical Microbiology, Central Hospital, Växjö, Sweden ABSTRACT It
More informationPlazomicin Versus Meropenem for the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis: Results of the EPIC Study
Plazomicin Versus Meropenem for the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis: Results of the EPIC Study Daniel J. Cloutier 1, Loren G. Miller 2, Allison S. Komirenko 1,
More informationOfficial reprint from UpToDate UpToDate, Inc. and/or its affiliates. All Rights Reserved.
Official reprint from UpToDate www.uptodate.com 2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved. Acute complicated cystitis and pyelonephritis Author: Thomas M Hooton, MD Section Editor:
More informationPREVENTION AND TREATMENT OF BACTERIAL INFECTIONS IN CIRRHOSIS
PREVENTION AND TREATMENT OF BACTERIAL INFECTIONS IN CIRRHOSIS Dr. J. Fernández. Head of the Liver Unit Hospital Clinic Barcelona, Spain AEEH Postgraduate Course, Madrid, February 15 2017 Prevalence of
More informationTherapeutic drug monitoring of β-lactams
CORATA Belgique Reims 1-2/10/2014 Therapeutic drug monitoring of β-lactams Frédéric Cotton Clinical Chemistry Erasme Hospital Faculty of Pharmacy ULB TDM of β-lactams β-lactams pharmacokinetics pharmacodynamics
More informationPhenotypic detection of ESBLs and carbapenemases
Phenotypic detection of ESBLs and carbapenemases Standardized susceptibility testing residential workshop 2016 Katie Hopkins PhD Clinical Scientist Antimicrobial Resistance and Healthcare Associated Infections
More informationContinuous Infusion of Antibiotics In The ICU: What Is Proven? Professor of Medicine Vice-Chairman, Department of Medicine SUNY at Stony Brook
Continuous Infusion of Antibiotics In The ICU: What Is Proven? Michael S. Niederman, M.D. Chairman, Department of Medicine Winthrop-University Hospital Mineola, NY Professor of Medicine Vice-Chairman,
More informationAnnual Surveillance Summary: Klebsiella Species Infections in the Military Health System (MHS), 2016
Annual Surveillance Summary: Klebsiella Species Infections in the Military Health System (MHS), 2016 Eboni Crawford and Uzo Chukwuma Approved for public release. Distribution is unlimited. The views expressed
More informationEvaluation of the in vitro activity of ceftazidime-avibactam and ceftolozane-tazobactam
AAC Accepted Manuscript Posted Online 14 March 2016 Antimicrob. Agents Chemother. doi:10.1128/aac.02969-15 Copyright 2016, American Society for Microbiology. All Rights Reserved. 1 2 Evaluation of the
More informationEpidemiology of ESBL in hospitals and in the community
Epidemiology of ESBL in hospitals and in the community Dietrich Mack Chair of Medical Microbiology and Infectious Diseases The School of Medicine - University of Wales Swansea P R I F Y S G O L C Y M R
More informationDecember 3, 2015 Severe Sepsis and Septic Shock Antibiotic Guide
Severe Sepsis and Septic Shock Antibiotic Guide Surviving Sepsis: The choice of empirical antimicrobial therapy depends on complex issues related to the patient s history, including drug intolerances,
More informationSWISS SUMMARY OF THE RISK MANAGEMENT PLAN (RMP) FOR ZERBAXA. (Ceftolozane/Tazobactam)
PAGE 1 SWISS SUMMARY OF THE RISK MANAGEMENT PLAN (RMP) FOR ZERBAXA (Ceftolozane/Tazobactam) Active substance(s): Ceftolozane/Tazobactam Product(s) concerned: ZERBAXA Market Authorisation Holder: MSD Merck
More informationCLINICAL CHARACTERISTICS AND ANTIBIOTIC RESISTANCE PATTERN OF PATHOGENS IN PEDIATRIC URINARY TRACT INFECTION
CLINICAL CHARACTERISTICS AND ANTIBIOTIC RESISTANCE PATTERN OF PATHOGENS IN PEDIATRIC URINARY TRACT INFECTION Yupaporn Amornchaicharoensuk Faculty of Medicine, Navamindradhiraj University, Bangkok, Thailand
More informationUrinary Tract Infections in Hospitalized Patients
Urinary Tract Infections in Hospitalized Patients Puerto Rico Chapter Annual Meeting Daniel C. DeSimone, MD March 9, 2019 2017 MFMER slide-1 Disclosures for speaker: Date of presentation: 3/9/2019 No relevant
More informationHUSRES Annual Report 2009 Martti Vaara
HUSRES Annual Report 2009 Martti Vaara www.huslab.fi www.intra.hus.fi Martti Vaara, 2/2010 1 The basis of this HUSRES 2009 report is the HUSLAB/Whonet database 2009, which contains susceptibility data
More informationUnidad Clínica de Enfermedades Infecciosas y Microbiología, Hospital Universitario Virgen Macarena, and 2 Departamentos de Medicina and 3
MAJOR ARTICLE b-lactam/b-lactam Inhibitor Combinations for the Treatment of Bacteremia Due to Extended-Spectrum b-lactamase Producing Escherichia coli: A Post Hoc Analysis of Prospective Cohorts Jesús
More informationA comparison of the clinical characteristics of elderly and non-elderly women with communityonset, non-obstructive acute pyelonephritis
ORIGINAL ARTICLE Korean J Intern Med 2015;30:372-383 A comparison of the clinical characteristics of elderly and non-elderly women with communityonset, non-obstructive acute pyelonephritis U-Im Chang,
More information10/4/16. mcr-1. Emerging Resistance Updates. Objectives. National Center for Emerging and Zoonotic Infectious Diseases. Alex Kallen, MD, MPH, FACP
National Center for Emerging and Zoonotic Infectious Diseases Emerging Resistance Updates Alex Kallen, MD, MPH, FACP Lead Antimicrobial Resistance and Emerging Pathogens Team Prevention and Response Branch
More informationXERAVATM (eravacycline): A Novel Fluorocycline Antibacterial
XERAVATM (eravacycline): A Novel Fluorocycline Antibacterial Matteo Bassetti, MD, PhD Infectious Diseases Division University of Udine and Santa Maria Misericordia University Hospital Udine, Italy Disclosures
More informationTranslocation Studies Mid-Term Review (MTR) Meeting Marseille, France
Marie Curie Actions Research Training Networks (RTN) Translocation Studies Mid-Term Review (MTR) Meeting Marseille, France F. Vidal-Aroca, M.G.P. Page and J. Dreier Background Deteriorating situation regarding
More informationInfection Control Strategies to Avoid Carbapenam Resistance in Hospitals. Victor Lim International Medical University Malaysia
Infection Control Strategies to Avoid Carbapenam Resistance in Hospitals Victor Lim International Medical University Malaysia Outline of Lecture 1. Carbapenam resistance 2. Epidemiology of carbapenam resistance
More informationGuidance on screening and confirmation of carbapenem resistant Enterobacteriacae (CRE) December 12, 2011
Guidance on screening and confirmation of carbapenem resistant Enterobacteriacae (CRE) December 12, 2011 Objectives: To discuss the guidelines for detection of CRE in the laboratory setting. To review
More informationNICE Guidance. NICE Guidance Complicated urinary tract infections: ceftolozane/tazobactam. Full Evidence Summary
This National Institute for Health and Care Excellence (NICE) guidance is the current, unaltered NICE guidance at time of publication. BJUI publishes selected NICE guidance relevant to urologists to extend
More informationORIGINAL ARTICLE SUSCEPTIBILITY PATTERNS IN GRAM NEGATIVE URINARY ISOLATES TO CIPROFLOXACIN, CO-TRIMOXAZOLE AND NITROFURANTOIN
SUSCEPTIBILITY PATTERNS IN GRAM NEGATIVE URINARY ISOLATES TO CIPROFLOXACIN, CO-TRIMOXAZOLE AND NITROFURANTOIN Anoop Sinha 1, Benny P V 2 HOW TO CITE THIS ARTICLE: Anoop Sinha, Benny PV. Susceptibility
More information